10x Genomics, Inc.
10x Genomics develops single cell and spatial multiomics instruments, assays, and software for biological research. The publicly traded company sells Chromium, Atera, Xenium, Visium, and Flex platforms to academic, biopharmaceutical, clinical, and computational biology customers globally.
- Company typePublic
- Founded2016
- HeadquartersPleasanton, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
10x Genomics, Inc. firmographics
Firmographics- Name
- 10x Genomics, Inc.
- Legal name
- 10x Genomics, Inc.
- Website
- https://10xgenomics.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- 10x Genomics develops single cell and spatial multiomics instruments, assays, and software for biological research. The publicly traded company sells Chromium, Atera, Xenium, Visium, and Flex platforms to academic, biopharmaceutical, clinical, and computational biology customers globally.
- Ownership category
- akta.pro rank
10x Genomics, Inc. industry classification
Industry- Product category
- Single Cell and Spatial Biology Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
- akta.pro secondary industries
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where 10x Genomics, Inc. is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
10x Genomics, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Instrument Sales: Sale of capital equipment including Chromium X Series instruments, Atera, Xenium Analyzer, and Visium CytAssist. Instrument revenue declined 36% in Q4 2025 and 39% for full year 2025, reflecting challenging capital equipment funding environment.
- Consumables and Reagents: Recurring revenue from reagents, kits, and consumables for single cell and spatial biology assays. Consumables revenue grew 6% in Q4 2025 and 3% for full year 2025, representing the majority of product revenue.
- Services: Service revenue from sample processing and research services. Services revenue showed strong growth with 48% increase in Q3 2025.
- Software and Cloud Analysis: Cloud-based data analysis platform providing software-as-a-service capabilities for processing 10x Genomics data
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Enterprise instruments (Chromium X Series, Atera, Xenium Analyzer, Visium CytAssist) |
| Usage-based | Pay-as-you-go | Atera Catalyst Research Services |
| Unit Pricing | Pay-as-you-go | Reagents, kits, and consumables |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
10x Genomics, Inc. product offering
Product offeringCore offering
10x Genomics develops and sells single cell and spatial multiomics platforms comprising capital instruments (Chromium, Atera, Xenium, Visium CytAssist), proprietary consumables and reagent kits, and analysis software (Cell Ranger, Cloud Analysis, Loupe Browser). Its products profile individual cells, detect rare populations, map spatial gene expression in tissues, and generate multiomic datasets for academic, translational, biopharmaceutical, and clinical research customers.
Differentiator
Problem solved
Functional benefit
Brands
- Atera: In situ spatial biology platform for whole-transcriptome spatial analysis at unprecedented scale with single-cell sensitivity.
- Chromium
- Xenium
- Visium
- Flex
Products and services
- Chromium Single Cell Droplet-based single cell multiomics platform for profiling gene expression, immune repertoire, chromatin accessibility, and multiomic features across thousands of samples and billions of cells, including from FFPE tissue.
- Atera In Situ Scalable in situ spatial biology platform providing whole-transcriptome coverage at single-cell sensitivity, enabling high-throughput spatial gene expression analysis on intact tissue.
- Xenium In Situ High-plex in situ imaging platform for subcellular profiling of RNA targets from fresh frozen or FFPE tissues, integrating high-resolution imaging with onboard data analysis.
- Visium Spatial NGS-based spatial gene expression platform providing whole-transcriptome spatial analysis at single-cell scale, with CytAssist-enabled workflow for FFPE and fresh frozen tissue samples.
- Flex / Flex Apex Plate-based multiplexing single cell assay (Flex Apex) for profiling FFPE and fixed whole blood samples using Chromium Precision chemistry, with massive-throughput plate-based workflows.
- Cell Ranger & Analysis Software Suite of free and cloud-based analysis pipelines, including Cell Ranger for data processing, Cloud Analysis for hosted analysis, and Loupe Browser for visualization, supporting 10x Genomics single cell and spatial data.
Quantifiable outcome
- Up to 80% cell recovery efficiency with GEM-X chemistry
- +4 more outcomes
Companies that use 10x Genomics, Inc.
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles5 records
10x Genomics, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
10x Genomics, Inc. partnerships and signals
Strategic signalPartnerships
24 partnerships are on record, tiered strategic and core.
- RochestrategicCollaboration supporting Roche's AXELIOS 1 next-generation sequencing platform launch, with 10x Genomics providing technology integration for data analysis capabilities. Positions 10x in sequencing market valued at USD 7.3 billion.
- Cleveland CliniccoreMulti-year research collaboration to analyze advanced bladder cancer tumor samples using Flex Apex, Xenium, and Atera spatial biology platforms to identify biomarkers predicting patient response to antibody-drug conjugate treatments. Study will examine tumor samples from patients undergoing ADC and immunotherapy treatments, generating comprehensive multimodal datasets linking single cell and spatial profiles with clinical outcomes.
- Proteintech GenomicscoreAcquisition of Proteintech Genomics, a division within Proteintech Group, expanding 10x's proteomics capabilities in single cell and spatial biology. The acquisition brings the Human Discovery Panel, the largest antibody-based single cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles within sequencing-compatible workflows.
- University of Pennsylvania (Carl June Lab)strategicAtera early access partner that generated data demonstrating platform's capabilities, including identification of rare immune cell populations and mapping of tumor microenvironments.
- BioptimuscoreSTELA (Spatial Tissue Embedding Learning Atlas) initiative anchored by 10x Genomics' Xenium platform, aiming to profile up to 100,000 patient tissue specimens across three continents (~20-fold increase over existing atlases). Serves as data backbone for M-Optimus multimodal world model of biology. Commercial expansion to Atera planned for 2027.
- Broad Clinical LabscoreStrategic partner in STELA initiative contributing high-throughput laboratory workflows for generating harmonized multi-omics patient data across the 100,000-specimen atlas.
- PerturbAIstrategicCollaboration producing world's largest in vivo CRISPR atlas with 8 million brain-wide cells using Perturb-seq technology. 10x Genomics provided technology for generating the largest known causal genomics resource in living tissue for drug discovery and AI model training.
- Allen Institute for Brain SciencestrategicCollaboration partner in PerturbAI's 8M cell CRISPR atlas project, contributing to world's largest in vivo causal genomics resource for mouse brain research.
- NVIDIAstrategicTechnology partner providing accelerated computing infrastructure for PerturbAI's in vivo CRISPR atlas project and causal AI model development.
- Stanford University School of MedicinestrategicPartner in CRI Discovery Engine initiative alongside 10x Genomics, Stanford University, Penn Medicine, and Memorial Sloan Kettering to standardize and pool cancer immunotherapy research for AI-driven breakthroughs.
- University of Pennsylvania Perelman School of MedicinestrategicPartner in CRI Discovery Engine initiative to create shared data infrastructure for cancer immunotherapy research enabled by 10x platforms.
- Memorial Sloan Kettering Cancer CenterstrategicPartner in CRI Discovery Engine initiative to standardize cancer immunotherapy research data infrastructure with 10x Genomics spatial and single cell platforms.
- PharosAIcoreUK research consortium backed by £18.9 million government funding using Xenium spatial platform to build one of world's largest multimodal cancer datasets. Initiative will transform archived NHS cancer samples into high-resolution AI-ready datasets, initially focusing on breast cancer before expanding to lung and pancreatic cancer through 2027.
- Dana-Farber Cancer InstitutecoreMulti-year collaboration analyzing tumor samples from hundreds of patients with major solid cancer types using Chromium Flex single cell assay and Xenium spatial platform. Research aims to identify biomarkers and develop clinical reporting framework for precision oncology treatments including ADCs, radioligand therapies, and bispecific antibodies.
- Brigham and Women's HospitalcoreCollaboration analyzing peripheral blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using Chromium Flex single-cell assay. Research aims to identify immune signatures associated with disease activity, flare, remission, and therapeutic response.
- Cancer Research InstitutecoreAI-driven immuno-oncology initiative involving over 20,000 samples to build comprehensive dataset for future cancer treatments and vaccines using high-resolution biological data from 10x platforms.
- CareDxcoreImmuneScape multiomics research initiative leveraging Xenium spatial and Chromium Flex platforms to study transplant organ rejection at cellular resolution. Program will generate high-resolution maps of immune mechanisms underlying antibody-mediated rejection and microvascular inflammation to support future clinical diagnostic development.
- AnthropicstrategicIntegration of Anthropic's Claude for Life Sciences AI platform with 10x Genomics' single cell and spatial biology analysis platforms. Enables researchers to access, analyze, and interpret biological datasets through cloud-based interfaces for automated QC, gene/protein interaction analyses, and multi-step workflows.
- Beckman Coulter Life SciencesstrategicCollaboration since 2023 to automate single cell gene expression workflows, enabling processing capacity increase to 96 samples per day vs 24 with manual methods, reducing hands-on time from over 5 hours to 1 hour.
- Arc InstitutecoreVirtual Cell Atlas initiative using Flex platform to generate 300M+ cell CRISPR perturbational dataset to fuel AI cell models that predict cellular responses and accelerate therapeutic target discovery.
- Chan Zuckerberg InitiativecoreBillion Cells Project using Chromium technology for landmark single cell dataset to deepen understanding of cellular behavior and gene function (1B cells).
- OwkinstrategicMOSAIC (Multi-Omics Spatial Atlas In Cancer) initiative using Visium and Flex technologies for massive pan-cancer spatial transcriptomics dataset (7,000 FFPE tissues) to enable AI-based therapeutic prediction modeling.
- Xaira TherapeuticsstrategicX-Atlas/Orion initiative using Universal 5' platform for largest publicly available Perturb-seq atlas targeting all human protein-coding genes for foundational model training (8M cells).
- Ultima GenomicsstrategicPartnership combining 10x Genomics single cell and spatial sequencing quality with Ultima's ultra-low-cost sequencing capacity to unlock biological insights at large scales.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
10x Genomics, Inc. competitors and assessment
Company assessmentDirect peers
- Parse Biosciences: Direct competitor in single-cell RNA sequencing with an instrument-free, combinatorial barcoding chemistry (Evercode). Targets the same academic and translational single-cell market as Chromium with a different deployment model.
- Standard BioTools (formerly Fluidigm): Direct peer in single-cell biology through mass cytometry (CyTOF/Hyperion imaging mass cytometry) and microfluidics-based single-cell workflows, competing for similar translational and immunology research customers.
- Singleron Biotechnologies: Single-cell transcriptomics competitor offering the Microwell-seq-based Singleron Matrix and AccuraSCOPE platforms, particularly active in Asia-Pacific translational and clinical research markets overlapping with 10x.
- Akoya Biosciences: Direct competitor in high-plex spatial biology through the CODEX/PhenoCycler platform, overlapping with Xenium in tissue imaging and multiplexed spatial phenotyping for translational research.
- Bruker Spatial Biology (formerly NanoString Technologies): Direct competitor in spatial transcriptomics via the CosMx SMI platform and GeoMx Digital Spatial Profiler. Most head-to-head rival to 10x's Xenium and Atera in the in situ spatial biology market.
Broad incumbents
- BD Biosciences (Becton Dickinson): Broad incumbent with the BD FACSDiscover S8 sorter combining spectral flow cytometry with imaging, plus cell sorting and single-cell genomics reagents. Competes for single-cell biology budgets across pharma and academic customers.
- Pacific Biosciences: Long-read sequencing incumbent (Revio, Onso) increasingly bundled with single-cell workflows through partnerships with 10x-compatible kit providers; competes for translational genomics research budgets.
- Illumina: Dominant next-generation sequencing incumbent whose platforms underpin 10x's NGS-based assays (Visium, Chromium); also develops connected-annotation and single-cell partnerships that compete with 10x-enabled workflows.
- Bio-Rad Laboratories: Broad life science tools incumbent offering ddPCR, single-cell ATAC-seq (ATAC-Seq), and ZE5 cell analyzers, with overlapping presence in genomics and cell biology research labs that purchase 10x instruments.
Emerging players
- Element Biosciences: Emerging sequencing platform (AVITI) pursuing cost-competitive short-read sequencing; competes for benchtop NGS budgets where 10x's Visium and Chromium workflows are deployed, with potential partnership overlap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
10x Genomics, Inc. social profiles
Digital presence10x Genomics, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
10x Genomics, Inc. leadership team
Management profileNumber of profiles
Profiles5 records
10x Genomics, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
10x Genomics, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 10x Genomics, Inc.
What does 10x Genomics, Inc. do?
10x Genomics develops and sells single cell and spatial multiomics platforms comprising capital instruments (Chromium, Atera, Xenium, Visium CytAssist), proprietary consumables and reagent kits, and analysis software (Cell Ranger, Cloud Analysis, Loupe Browser). Its products profile individual cells, detect rare populations, map spatial gene expression in tissues, and generate multiomic datasets for academic, translational, biopharmaceutical, and clinical research customers.
Is 10x Genomics, Inc. a public or private company?
10x Genomics, Inc. is a public company. It is classified as public and is currently operating.
When was 10x Genomics, Inc. founded?
10x Genomics, Inc. was founded in 2016. It employs 1,001 to 5,000 people.
Where is 10x Genomics, Inc. based?
10x Genomics, Inc. is headquartered in Pleasanton, United States, in the North America region.
How does 10x Genomics, Inc. make money?
Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables and Reagents, services and software and Cloud Analysis.
Who are 10x Genomics, Inc.'s main competitors?
Direct peers on record are Parse Biosciences, Standard BioTools (formerly Fluidigm), Singleron Biotechnologies, Akoya Biosciences and Bruker Spatial Biology (formerly NanoString Technologies). Broad incumbents are BD Biosciences (Becton Dickinson), Pacific Biosciences, Illumina and Bio-Rad Laboratories. Element Biosciences is listed as an emerging player.
Does 10x Genomics, Inc. have an API?
No public API is recorded for 10x Genomics, Inc..
What industry is 10x Genomics, Inc. in?
10x Genomics, Inc.'s product category is Single Cell and Spatial Biology Instruments. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 334516 and its SIC code is 3826.